CardioNerds @AHA23: SELECT: Effects of Semaglutide on Heart Disease & Stroke in Obese Patients

Published: 21 Nov 2023

  • Views:

    Views Icon 575
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

AHA 2023 - Investigator, Dr A Michael Lincoff (Cleveland Clinic, US) is interviewed by Dr Ahmed Ghoneem (UPMC Harrisburg, US), CardioNerds Ambassador, on the findings of the SELECT Trial (NCT03574597).

SELECT is a randomised trial aiming to determine if semaglutide can reduce the risk of cardiovascular events in patients with overweight or obesity and prior cardiovascular disease. 17609 patients were enrolled in the trial, and were randomized to receive either semaglutide or placebo. 

The once-weekly subcutaneous injection of semaglutide 2.4 mg resulted in a 20% reduction in the risk of cardiovascular death, myocardial infarction (MI) or stroke. This benefit was observed early and consistently across various subgroups and cardiovascular endpoints.

Recorded on-site at AHA 2023, Philadelphia.

Supported by an educational grant from Novo Nordisk Inc. This content is not intended for UK HCPs.


You must be to comment. If you are not registered, you can register here.